Back to Journals Drug Design, Development and Therapy Volume 20 GLP-1 Receptor Agonists in Neurological Disorders: From Mechanisms to Clinical Translation Received 1 April 2026 Accepted for publication 2 June 2026 Published 12 June 2026 Volume 2026:20 613616 DOI Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Professor Anastasios Lymperopoulos Pengpeng Li, Yangyang Gao, Wei Liu Department of Neurosurgery, Xian Aerospace Hospital of Northwest University, Xian, Shanxi, 710000, Peoples Republic of China Correspondence: Pengpeng Li, Email [email protected] Wei Liu, Email [email protected] Abstract: Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, have been used for years to treat type 2 diabetes and obesity
This comparison breaks down what each does, how they differ, and why their combination (CagriSema) may represent the next leap in obesity pharmacotherapy
Frequently Asked Questions What is the dosing schedule for retatrutide used in clinical trials
a good healthcare provider will listen to your environmental concerns and be willing to investigate them thoroughly
Critical when titration precision determines both efficacy and tolerability
La creatina suele ser ms fuerte para el posicionamiento del rendimiento, mientras que la L-carnitina es til para el metabolismo energtico y el apoyo al metabolismo de las grasas
